文献速递药物不良反应与药物警戒特殊人群用药

甲氨蝶呤药物基因组学变异预测儿童急性淋巴细胞白血病急性神经毒性的评价

Evaluation of methotrexate Pharmacogenomic variation to predict acute neurotoxicity in children with acute lymphoblastic leukemia.
PubMed 文献 · Pharmacotherapy · 2024-12-29

本研究纳入美国西南部六家治疗中心2005至2019年确诊的763例2-20岁急性淋巴细胞白血病患儿,评估97个甲氨蝶呤药物基因组学变异与神经毒性的关联。8.2%患儿发生甲氨蝶呤相关神经毒性,多变量模型中无变异达统计学显著,ABCC2 rs17222723与ABCB1 rs1045642仅名义相关,加入变异未改善随机森林预测性能。

要点

  • 97个甲氨蝶呤药物基因组学变异均未与神经毒性达校正后显著关联。
  • ABCC2 rs17222723与ABCB1 rs1045642仅呈名义相关(P<0.05)。
  • 加入药物基因组学变异未改善神经毒性风险分层预测。

核心结论

  • 甲氨蝶呤药物基因组学变异与儿童ALL神经毒性易感性的关联总体微弱,未显著改善风险分层。

研究设计与样本

  • 多中心回顾性队列研究,纳入2005-2019年美国西南部六家中心确诊ALL的2-20岁儿童763例。
  • 神经毒性事件由至少两名儿科肿瘤学家独立评审,定义为静脉和/或鞘内甲氨蝶呤后21天内发生的事件。
  • 对97个至少有3级证据的甲氨蝶呤药物基因组学变异进行基因分型,采用逻辑回归评估关联,并按80/20随机拆分数据构建随机森林模型评估分类能力。

主要发现

  • 763例患儿中8.2%(n=63)发生甲氨蝶呤相关神经毒性。
  • 逻辑回归模型中97个变异均未达校正后统计学显著。
  • ABCC2 rs17222723(OR=2.83,参考等位基因为T,95%CI:1.20-6.15)与ABCB1 rs1045642(OR=0.66,参考等位基因为次要A等位基因,95%CI:0.44-0.98)与神经毒性易感性仅名义相关(P<0.05)。
  • 加入药物基因组学变异后随机森林模型AUC=0.73,未优于仅用临床信息的AUC=0.74。

临床怎么用

  • 当前证据不支持将所评估的甲氨蝶呤药物基因组学变异用于儿童ALL神经毒性风险分层。
  • 临床仍应以临床信息为主要依据评估甲氨蝶呤神经毒性风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Methotrexate is an important component of curative therapy in childhood acute lymphoblastic leukemia (ALL), but the role of genetic variation influencing methotrexate clearance and transport in toxicity susceptibility in children with ALL is not well established. Therefore, we evaluated the association between suspected methotrexate pharmacogenomic variants and methotrexate-related neurotoxicity. METHODS: This study included children (aged 2-20 years) diagnosed with ALL (2005-2019) at six treatment centers in the southwest United States. Clinical information was abstracted from medical records. Suspected neurotoxic events occurring within 21 days of intravenous and/or intrathecal methotrexate delivered between the end of induction and start of maintenance therapy were independently reviewed by at least two pediatric oncologists. Germline DNA was genotyped and 97 methotrexate pharmacogenomic variants of interest with at least grade 3 evidence were identified using the Pharmacogenomics Knowledge Base. Associations between variants and neurotoxicity were assessed by logistic regression. Data were randomly split (80/20) and random forest was constructed to estimate the ability of the variants to correctly classify neurotoxicity. RESULTS: Of the 763 patients included in the study, 8.2% (n = 63) developed methotrexate-associated neurotoxicity. In logistic models, none of the 97 available pharmacogenomic variants reached adjusted statistical significance. However, two variants, rs17222723 (odds ratio [OR] = 2.83 [ref. = T allele], 95% confidence interval [CI]: 1.20-6.15) in ABCC2 and rs1045642 (OR = 0.66 [ref. = minor A allele], 95% CI: 0.44-0.98) in ABCB1, were nominally associated (p-value < 0.05) with neurotoxicity susceptibility. The addition of pharmacogenomic variants did not improve the predictive performance of random forest model (AUC = 0.73) compared to clinical information alone (AUC = 0.74). CONCLUSION: Overall, our results suggest that associations between neurotoxicity susceptibility and methotrexate pharmacogenomic variants are generally modest and these variants do not significantly improve neurotoxicity risk stratification among children with ALL.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Harris RD, Taylor OA, Gramatges MM, et al. Evaluation of methotrexate Pharmacogenomic variation to predict acute neurotoxicity in children with acute lymphoblastic leukemia. Pharmacotherapy. 2024. PMID: 39734275. doi:10.1002/phar.4638

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。